oral semaglutide brand name Novo says it's submitted obesity

[1] [3] This may result in gastroesophageal reflux disease (GERD) or laryngopharyngeal reflux (LPR) with symptoms such as a taste of acid in the back of the mouth or heartburn

The ingredient is broken down in 24 hours, so it can be used intermittently without having to titrate dosages up or down

Wegovy is FDA-approved for weight loss and, in March 2024, it became the first FDA-approved treatment to reduce the risk of major cardiovascular events in adults with overweight or obesity

Gradual dose titration, as recommended in the Summary of Product Characteristics, helps minimise gastrointestinal disturbance

Proliferation control in neural stem and progenitor cells